CardioDx appoints Lange as board chair
CardioDx, a cardiovascular genomic diagnostics company, has appointed Louis G. Lange, MD, PhD, as chairman of its board of directors.
Lange has more than 20 years’ experience in medicine at Harvard University in Cambridge, Mass., and Washington University in Seattle, where he served as chief of cardiology. Recently, Lange founded CV Therapeutics, where he served as chairman and CEO from 1992 to 2009, overseeing the commercialization of its cardiovascular product portfolio. Lange also sits on the boards of Maxygen, Metabolex and Synecor.
Lange has more than 20 years’ experience in medicine at Harvard University in Cambridge, Mass., and Washington University in Seattle, where he served as chief of cardiology. Recently, Lange founded CV Therapeutics, where he served as chairman and CEO from 1992 to 2009, overseeing the commercialization of its cardiovascular product portfolio. Lange also sits on the boards of Maxygen, Metabolex and Synecor.